Skip to main content

Table 7 Incremental cost-effectiveness ratios in 2002 prices for the preferred (not dominated) strategies from Bolin et al. [10], assuming a 10-year dwell time

From: Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia

Strategy

Cost ($)

Incremental changes in cost ($)

Effectiveness (LYG)

Incremental changes in effectiveness (LYG)

Average cost-effectiveness ratio ($)

Incremental cost-effectiveness ratio ($)

 

(a)

(b)

(c)

(d)

(a)/(c)

(b)/(d)

EXISTING PRACTICE

0

 

0

 

(Undefined)

 

FOBT2

140,117,791

140,117,791

3,551

3,551

39,459

39,459

DCBE5

248,112,291

107,994,500

6,023

2,472

41,194

43,687

DCBE3

304,301,903

56,189,612

6,720

697

45,283

80,616

FOBT1+DCBE5

370,181,240

65,879,337

7,076

356

52,315

185,054

FOBT1+DCBE3

422,777,702

52,596,462

7,299

223

57,923

235,859

  1. Note: Other options rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussion